|
Dr. Kornblith trained in neurosurgery at Massachusetts General Hospital, joined the faculty of Harvard University, and became Principal Investigator of an NIH program project in brain tumor biology. He improved techniques for studying human brain tumors in tissue culture, defining their biochemical, biophysical and ultrastructural characteristics. As Chief of Surgical Neurology at NIH, his work led to the development of a chemosensitivity assay which was modified into the now-standard screen for studying new prospective chemotherapy agents. He was the leader of the NIH PET program and discovered its value in clinical cancer management. As the Bergstein Professor of Neurosurgery and Chairman at Albert Einstein College of Medicine and Montefiore Medical Center, his group’s research led to the discovery of the role of B-FGG in promoting brain tumor growth. At the University of Pittsburgh, he was Professor of Neurosurgery and Vice Chairman, focusing his research on control of brain tumor invasiveness by growth factors and immunologically active cytokines. Presently, Dr. Kornblith is Adjunct Professor at the University of Pittsburgh School of Health and Rehabilitation Sciences. In 1995, he founded and served as President and CEO of Precision Therapeutics, Inc., a cancer chemoresponse company, where he is now the Founder and Chairman Emeritus. He is Western Pennsylvania Regional Director for PABiotech and was appointed by former Pennsylvania Governor Tom Ridge to the Health Research Advisory Committee. | 